Regenacy Pharmaceuticals, LLC

San Francisco start-up 3T Biosciences came out of stealth mode on 25 August with $40m in new venture capital from a series A round led by Westlake Village BioPartners with participation from Lightsp

Stock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture

Company Changes AGARWAL , Sunil, MD To: Juno Therapeutics Inc. , Pres., R&D (April) From: Ultragenyx Pharmaceutical Inc., EVP, CMO Phone: 206-582-1600 AL-WAKEEL Yasir To: Neon Therapeutics

Financings Biopharma companies closed out 2016 with $9.6 billion in financing. ( See Exhibit 1. ) Not only was this a 30% increase over Q3's $7.4 billion, it was also the strongest quarter of the year